This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
What to Expect for Universal Health's (UHS) Q3 Earnings
by Zacks Equity Research
Universal Health (UHS) is likely to have benefited from strong segmental performances at Acute Care and Behavioral Health in Q3, partly offset by high costs.
Anthem (ANTM) Gears Up for Q3 Earnings: What's in Store?
by Zacks Equity Research
Anthem (ANTM) is likely to have gained from solid revenues in the third quarter.
What's in the Cards for Centene's (CNC) Earnings in Q3?
by Zacks Equity Research
Centene's (CNC) third-quarter earnings are likely to have grown on the back of solid revenues.
MEDNAX (MD) to Sell MedData for Focusing on Core Business
by Zacks Equity Research
MEDNAX (MD) to divest its billing services business for streamlining its operations.
MEDNAX Teams Up With CENTA to Expand Services in Florida
by Zacks Equity Research
MEDNAX (MD) inks a partnership deal with CENTA to strengthen its profile of varied healthcare solutions in Florida.
Mednax Collaborates With Northern Indiana Neonatal Associates
by Zacks Equity Research
Mednax (MD) joins forces with Northern Indiana Neonatal Associates in Fort Wayne to enhance its neonatal services.
Mednax (MD) Down 5.1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Mednax (MD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is MEDNAX (MD) a Profitable Stock for Value Investors Now?
by Zacks Equity Research
Let's see if MEDNAX (MD) stock is a good choice for value-oriented investors right now from multiple angles.
MEDNAX's (MD) Earnings Beat Estimates in Q2, Decrease Y/Y
by Zacks Equity Research
Mednax's (MD) Q2 gains on revenue growth, partly offset by rise in expenses.
Mednax (MD) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Mednax (MD) delivered earnings and revenue surprises of 2.30% and 0.07%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Is a Beat in Store for Molina Healthcare (MOH) Q2 Earnings?
by Zacks Equity Research
Molina Healthcare's (MOH) second-quarter earnings are likely to be cushioned by its strategic divestitures as well as cost-reduction plans, partly offset by lower revenues.
Is a Beat in the Cards for Humana's (HUM) Earnings in Q2?
by Zacks Equity Research
Humana's (HUM) second-quarter earnings are likely to gain traction from a solid revenue stream.
What's in the Cards for HCA Healthcare's (HCA) Q2 Earnings?
by Zacks Equity Research
HCA Healthcare's (HCA) Q2 earnings are likely to be aided by higher admissions and revenues, partly offset by escalating expenses.
WellCare Health's (WCG) Q2 Earnings: What's in Store?
by Zacks Equity Research
WellCare Health's (WCG) Q2 earnings are likely to be supported by higher membership.
Mednax (MD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Mednax (MD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MEDNAX Forges Alliance for Better Health Services in Texas
by Zacks Equity Research
MEDNAX (MD) collaborates with Alfredo Gei MD, P.A. to provide patients with better healthcare services in Houston.
Why Is Mednax (MD) Down 12.3% Since Last Earnings Report?
by Zacks Equity Research
Mednax (MD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
MEDNAX (MD) Q1 Earnings Miss Estimates, Decline Y/Y
by Zacks Equity Research
MEDNAX's (MD) first-quarter earnings disappoint with weak revenues and elevated expenses.
Mednax (MD) Q1 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Mednax (MD) delivered earnings and revenue surprises of -8.45% and -5.89%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Mednax (MD) Q1 Earnings Expected to Decline
by Zacks Equity Research
Mednax (MD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MEDNAX Ties Up With Georgia Neonatology for Better Baby Care
by Zacks Equity Research
MEDNAX (MD) forms a partnership with Georgia Neonatology, LLC to improve its pediatric services.
Why Is Mednax (MD) Down 17.6% Since Last Earnings Report?
by Zacks Equity Research
Mednax (MD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
MEDNAX (MD) Q4 Earnings Surpass Estimates, Increase Y/Y
by Zacks Equity Research
Mednax's (MD) Q4 gains on revenue growth. However, the same is partly offset by rise in expenses.
Mednax (MD) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Mednax (MD) delivered earnings and revenue surprises of 1.10% and 2.81%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
What Lies Ahead for Centene (CNC) Stock in Q4 Earnings?
by Zacks Equity Research
Centene's (CNC) fourth-quarter earnings are likely to gain traction from growth in revenues and membership strength, partly offset by high operating costs.